Halozyme scores $30M in cash for its latest alliance; Bernie Sanders takes aim at $375,000 rare disease drug
→ Now it’s argenx’s turn to sign up on a collaboration deal with Halozyme aimed at using their platform tech to create subcutaneous versions of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
